Pharma Companies Get On Board With Regeneron To Speed Biobank Sequencing
AbbVie, Alnylam, AstraZeneca and Pfizer join forces with Regeneron to speed up the sequencing of the 500,000 genetic samples in the UK's Biobank.
You may also be interested in...
Regeneron advocates industry-FDA collaboration to establish regulatory standards for novel applications of genomic data, such as determining whether long-term outcomes studies are needed, and inclusion of the data in product labeling.
AstraZeneca has entered into a series of early research collaborations in a bid to integrate genomics into the foundations of its entire drug discovery and development infrastructure.
Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.